Spyre Therapeutics Stock Investor Sentiment
| SYRE Stock | 27.70 0.70 2.59% |
About 54% of Spyre Therapeutics' shareholders are presently thinking to get in. The analysis of the overall investor sentiment regarding Spyre Therapeutics suggests that some traders are interested. The current market sentiment, together with Spyre Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Spyre Therapeutics stock news signals to limit their universe of possible portfolio assets.
Spyre |
Spyre Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Spyre Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Spyre Therapeutics that are available to investors today. That information is available publicly through Spyre media outlets and privately through word of mouth or via Spyre internal channels. However, regardless of the origin, that massive amount of Spyre data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Spyre Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Spyre Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Spyre Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Spyre Therapeutics alpha.
Spyre Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 18531 shares by Scott Burrows of Spyre Therapeutics at 28.173 subject to Rule 16b-3 | 09/03/2024 |
2 | Spyre Therapeutics Shares Gap Down to 30.17 - MarketBeat | 09/23/2024 |
3 | Perceptive Advisors LLC Increases Stake in Spyre Therapeutics, Inc. - MarketBeat | 09/30/2024 |
4 | Syre Exec Says Its Inflection Point Time for TextileCircularity | 10/04/2024 |
5 | Acquisition by Sloan Sheldon of 400000 shares of Spyre Therapeutics at 27.46 subject to Rule 16b-3 | 10/16/2024 |
6 | Disposition of 300 shares by Albers Jeffrey W. of Spyre Therapeutics at 36.43 subject to Rule 16b-3 | 10/25/2024 |
7 | Spyre Therapeutics director sells shares worth 10,929 | 10/28/2024 |
8 | Disposition of 6700 shares by Albers Jeffrey W. of Spyre Therapeutics at 36.7631 subject to Rule 16b-3 | 11/06/2024 |
9 | Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update | 11/07/2024 |
10 | Spyre shares target raised to 71 on positive trial data | 11/12/2024 |
11 | Perceptive Advisors LLC Reduces Stake in Spyre Therapeutics Inc | 11/15/2024 |
12 | Spyre Therapeutics announces proposed secondary offering | 11/18/2024 |
13 | Fairmount Funds Management LLCs Strategic Acquisition in Oruka Therapeutics Inc | 11/22/2024 |
Complementary Tools for Spyre Stock analysis
When running Spyre Therapeutics' price analysis, check to measure Spyre Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Spyre Therapeutics is operating at the current time. Most of Spyre Therapeutics' value examination focuses on studying past and present price action to predict the probability of Spyre Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Spyre Therapeutics' price. Additionally, you may evaluate how the addition of Spyre Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |